
    
      Performed at Manuel Fajardo Surgical Clinical University Hospital in Havana, Cuba from
      September 2014 to April 2018, following a proof of concept open label study, with no control
      group in 20 patients diagnosed histologically in Fajardo Hospital or Oncology Institute, as
      Melanoma, primary cutaneous stage IIB-IIIA. All received conventional surgical treatment and
      oral Oncoxin-Viusid (25 ml 2 times a day for one year), where it was also indicated adjuvant
      treatment or chemotherapy. All were evaluated monthly the first year and semesterly the
      second year. Complying with the provisions of the Helsinki Act.
    
  